Kiniksa CMO John Paolini Exercises Derivatives, Nets 4,299 Shares

What Happened

• John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals International (KNSA), exercised/converting derivatives on September 1, 2026, representing 8,328 underlying shares. Concurrently, 4,029 shares were withheld to cover tax liabilities (payment code F) at $79.28 per share, totaling $319,419. After withholding, Paolini received a net 4,299 shares.
• On the same date he was also granted derivative awards (RSUs) totaling 33,450 units (6,700 and 26,750 RSUs) at $0.00 (award code A). Several exercised/conversion entries are reported with $0.00 proceeds reflecting conversion/settlement of derivative awards.

Key Details

• Transaction date: 2026-09-01 (filed 2026-09-03 — appears timely).
• Exercise/conversion (code M): 2,497; 1,624; 1,750; and 2,457 shares (total 8,328) converted into shares.
• Tax withholding/payment (code F): 4,029 shares withheld at $79.28 each = $319,419.
• Grants (code A): 6,700 RSUs and 26,750 RSUs granted on 9/1/2026 (total 33,450 RSUs).
• Net shares received by insider after withholding: 4,299 shares.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Notable footnotes: RSUs represent contingent rights to one Class A ordinary share (F1). Multiple RSU/option grants have staggered vesting schedules (see F2–F7), with vesting commencement dates ranging from Sept 1, 2022 through Sept 1, 2026.
• Transaction codes: M = option/derivative exercise or conversion; F = payment of exercise price or tax liability (share withholding); A = grant/award.

Context

• This appears to be a conversion/settlement of derivative awards (RSUs/options) with shares withheld to satisfy tax obligations — a common administrative step that is not an open‑market sale. The withholding (F) resulted in cash value of ~$319k.
• Such transactions frequently reflect routine vesting/settlement and tax withholding; they do not necessarily signal a bullish or bearish view by the insider.